The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Shahneen Kaur Sandhu
Honoraria - Amgen; Bristol-Myers Squibb; Merck; Merck Serono
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Wilson H. Miller
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunovaccine; LaRoche Posay; Merck; Novartis; Sanofi
Research Funding - Merck; Takara Bio
Expert Testimony - Merck
 
Christian U. Blank
Stock and Other Ownership Interests - Forty Seven; Neon Therapeutics; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Eva Muñoz-Couselo
No Relationships to Disclose
 
Howard A. Burris III
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - AstraZeneca (Inst); Celgene (Inst); FORMA Therapeutics (Inst); Incyte (Inst)
Research Funding - Agios (Inst); Archer (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kyocera (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis (Inst)
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo (Inst); Pfizer (Inst)
 
Michael A. Postow
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; Merck; Newlink Genetics; Novartis
Research Funding - Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst)
 
Bartosz Chmielowski
Consulting or Advisory Role - Array BioPharma; Biothera; Compugen; Deciphera; Epizyme; HUYA Bioscience International; IDEAYA Biosciences; Iovance Biotherapeutics; Janssen; Regeneron
Speakers' Bureau - Janssen Oncology; Sanofi/Regeneron
Research Funding - Advenchen Laboratories (Inst); Aeglea Biotherapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly/ImClone (Inst); Macrogenics (Inst); Merck (Inst); Neon Therapeutics (Inst); PACT Pharma (Inst); RAPT Therapeutics (Inst); Rgenix (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Compugen; Deciphera; Epizyme; HUYA Bioscience International; IDEAYA Biosciences; Iovance Biotherapeutics; Regeneron
 
Mark R. Middleton
Consulting or Advisory Role - BiolineRx; Bristol-Myers Squibb; Immunocore; Johnson & Johnson; Merck; Vaccitech; Vista Pharmacueticals
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Vertex (Inst)
(OPTIONAL) Uncompensated Relationships - GenesisCare
 
Carola Berking
Honoraria - Bristol-Myers Squibb; Immunocore; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; LEO Pharma; Merck Serono; Miltenyi Biotec; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi/Regeneron; Sun Pharma
Research Funding - 4SC (Inst); Amgen (Inst); Array BioPharma (Inst); Biofrontera (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; LEO Pharma; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Jessica Cecile Hassel
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD; Pierre Fabre; Sun Pharma
Research Funding - 4SC (Inst); Amgen (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Idera (Inst); Immunocore (Inst); Novartis (Inst); Philogen (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Pierre Fabre
 
Anja Gesierich
Honoraria - Bristol-Myers Squibb; Novartis; Roche Pharma AG
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche Pharma AG; Sanofi/Aventis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche Pharma AG
 
Cornelia Mauch
Honoraria - Bristol-Myers Squibb; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Sanofi
 
Joseph Kleha
Employment - Pfizer
 
Ashwin Gollerkeri
Employment - Alnylam (I); Array BioPharma; Bluebird Bio (I); Pfizer
Stock and Other Ownership Interests - Alnylam (I); Array BioPharma; Bluebird Bio (I); Pfizer
Patents, Royalties, Other Intellectual Property - Receives royalties from Yale University on an antibody used in nephrology basic research. (I)
 
Allison Harney
Employment - Pfizer
 
Michael D Pickard
Employment - Pfizer
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Immunocore; Incyte; Italfarmaco; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; Syndax; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme